Glaxo Sales Drop As FDA Hearings Approach
The troubles over GlaxoSmithKline PLC's diabetes drug, Avandia, have just been compounded in the days leading up to a U.S. Food and Drug Administration advisory hearing over its safety....To view the full article, register now.
Already a subscriber? Click here to view full article